In two PhI­II wins for Al­ler­gan/Mol­e­c­u­lar Part­ners, wet AMD drug shows non-in­fe­ri­or­i­ty to Lu­cen­tis

It’s good news for Al­ler­gan and Mol­e­c­u­lar Part­ners’ wet AMD drug. The duo an­nounced Thurs­day that abic­i­par has met its end­points in two Phase III tri­als, prov­ing non-in­fe­ri­or­i­ty to the mar­ket-lead­ing Lu­cen­tis.

In both 8- and 12-week reg­i­mens, abic­i­par met its pri­ma­ry end­points, but al­so showed the in­ci­dence of in­traoc­u­lar in­flam­ma­tion was high­er in pa­tients on abic­i­par than those on Lu­cen­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.